Cargando…

Genetically Modified Cellular Therapies for Malignant Gliomas

Despite extensive preclinical research on immunotherapeutic approaches, malignant glioma remains a devastating disease of the central nervous system for which standard of care treatment is still confined to resection and radiochemotherapy. For peripheral solid tumors, immune checkpoint inhibition ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kilian, Michael, Bunse, Theresa, Wick, Wolfgang, Platten, Michael, Bunse, Lukas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657496/ https://www.ncbi.nlm.nih.gov/pubmed/34884607 http://dx.doi.org/10.3390/ijms222312810

Ejemplares similares

Clinical and Translational Advances in Glioma Immunotherapy
por: Bunse, Lukas, et al.
Publicado: (2022)

Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
por: Elmadany, Nirmeen, et al.
Publicado: (2022)

K27M-mutant histone-3 as a novel target for glioma immunotherapy
por: Ochs, Katharina, et al.
Publicado: (2017)

Dysfunctional dendritic cells limit antigen-specific T cell response in glioma
por: Friedrich, Mirco, et al.
Publicado: (2022)

In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
por: Hunger, Jessica, et al.
Publicado: (2023)

Emerging targets for anticancer vaccination: IDH
por: Platten, M., et al.
Publicado: (2021)

T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells
por: Lu, Kevin Hai-Ning, et al.
Publicado: (2022)

T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
por: Kilian, Michael, et al.
Publicado: (2022)

Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes
por: Blobner, Jens, et al.
Publicado: (2021)

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
por: Bunse, Lukas, et al.
Publicado: (2022)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
por: Grassl, Niklas, et al.
Publicado: (2023)

Targeted therapy in the treatment of malignant gliomas
por: Lukas, Rimas V, et al.
Publicado: (2009)

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
por: Lin, Wen-Ying, et al.
Publicado: (2020)

A H3K27M-targeted vaccine in adults with diffuse midline glioma
por: Grassl, Niklas, et al.
Publicado: (2023)

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
por: Aslan, Katrin, et al.
Publicado: (2020)

The aryl hydrocarbon receptor in tumor immunity
por: Platten, Michael, et al.
Publicado: (2012)

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
por: Turco, Verena, et al.
Publicado: (2023)

Gene therapy for malignant glioma
por: Okura, Hidehiro, et al.
Publicado: (2014)

Human Cytomegalovirus Antigens in Malignant Gliomas as Targets for Adoptive Cellular Therapy
por: Landi, Daniel, et al.
Publicado: (2014)

Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas
por: Shirai, Katsuyuki, et al.
Publicado: (2012)

Autophagy as a Potential Therapy for Malignant Glioma
por: Escamilla-Ramírez, Angel, et al.
Publicado: (2020)

Impairments of Motor-Cortex Responses to Unilateral and Bilateral Direct Current Stimulation in Schizophrenia
por: Hasan, Alkomiet, et al.
Publicado: (2013)

Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma
por: Seidel, Clemens, et al.
Publicado: (2011)

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
por: Bunse, Lukas, et al.
Publicado: (2022)

Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
por: Ahluwalia, Manmeet S., et al.
Publicado: (2010)

Current and Future Gene Therapy for Malignant Gliomas
por: Kanzawa, Takao, et al.
Publicado: (2003)

Brain Tumor Networks in Diffuse Glioma
por: Yang, Yvonne, et al.
Publicado: (2022)

Genetically Engineered Multilineage-Differentiating Stress-Enduring Cells as Cellular Vehicles against Malignant Gliomas
por: Yamasaki, Tomohiro, et al.
Publicado: (2017)

Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma
por: Anssar, Tareq M., et al.
Publicado: (2019)

Lung toxicity of lomustine in the treatment of progressive gliomas
por: Seliger, Corinna, et al.
Publicado: (2022)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma
por: Rahman, Ruman, et al.
Publicado: (2010)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors
por: Costa, Barbara, et al.
Publicado: (2021)

Current FDA-Approved Therapies for High-Grade Malignant Gliomas
por: Fisher, Jacob P., et al.
Publicado: (2021)

Current available therapies and future directions in the treatment of malignant gliomas
por: Desjardins, Annick, et al.
Publicado: (2009)

Combining molecular targeted agents with radiation therapy for malignant gliomas
por: Scaringi, Claudia, et al.
Publicado: (2013)

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
por: Plate, Karl H., et al.
Publicado: (2012)

Genetic, cellular, and connectomic characterization of the brain regions commonly plagued by glioma
por: Mandal, Ayan S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rskagkm1021okatn82bcds0e40